STEATO-HEPATITIS IN OBESE PATIENTS SUBMITTED TO BARIATRIC SURGERY (BS): UTILITY OF CONTRAST-ENHANCED US WITH TIME- INTENSITY CURVES (CEUS-TIS) FOR DIAGNOSIS:

Slides:



Advertisements
Similar presentations
FibroMax in the most common liver diseases
Advertisements

Hcv infection and management in advanced liver disease
Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Diagnostic Accuracy of Serum Hyaluronic Acid for Advanced Fibrosis/Cirrhosis in Patients Coinfected with HIV and HCV S. Resino,* 1 P. Miralles, 2 D. Micheloud,
Liver Fibrosis Are Non-invasive markers sufficient? William Rosenberg Prof of Hepatology University of Southampton CSO iQur Limited; Consultant to Bayer.
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,
Liver Cirrhosis S. Diana Garcia
 Fatty liver disease can range from fatty liver alone (steatosis) to fatty liver associated with inflammation (steatohepatitis). This condition can occur.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Deranged LFTs Pathways A H Mohsen Dr A H Mohsen MD (KCL), MRCP, DTM&H Consultant Gastroenterologist.
F ATTY L IVER Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International.
Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.
THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.
UOG Journal Club: January 2013
Non-alcoholic Fatty Liver Disease
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.
Non-Invasive Liver Testing
Alcoholic Hepatitis Miriam Nojan PGY-2 April 2016.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Predicting Mortality in Non-Variceal Upper Gastrointestinal Bleeders: Validation of the Italian PNED Score and Prospective Comparison With the Rockall.
Thomas Sersté1,2, Vincent Barrau3, Violaine Ozenne1, Marie Pierre Vullierme3, Pierre Bedossa5,6, Olivier Farges4, Dominique-Charles Valla1,6, Valérie Vilgrain3,6,
Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease : The St Francis Heart Study Randomized Clinical Trial Temitope Foster,
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, and James E. Nelson ; for.
Diagnostic accuracy and statistical significance
No conflict of interest
Volume 41, Issue 6, Pages (December 2004)
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Persistence Of Vitamin D Deficiency In Asians And Duodenal Switch Patients After Bariatric Surgery Despite Supplements A Goralczyk1, T D L Williams2, E.
BY: Asmaa Alastal. wafaa hanouna. Salma abu taha. .Sara shaban
Bariatric Surgery in Cirrhotic Patients. Analysis of 12 cases.
University of Medicine and Pharmacy “Carol Davila”, Bucharest
Guidelines for the diagnosis and management of Nonalcoholic Fatty Liver Disease (NAFLD): Update in 2012 Sameh M Fakhry MD, Msc, PhD Consultant of Gastroenterology,
Volume 148, Issue 4, Pages (April 2015)
Flavia D. Mendes, Ayako Suzuki, Schuyler O. Sanderson, Keith D
The receiver operating characteristic (ROC) curve
Noninvasive Assessment of Hepatic Steatosis
Non-invasive diagnosis of non-alcoholic fatty liver disease
Figure 1 Proposed algorithm for the management
Perfusion Computerized Tomography Can Predict Pancreatic Necrosis in Early Stages of Severe Acute Pancreatitis  Yoshihisa Tsuji, Hiroshi Yamamoto, Shujiro.
Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease  Kathleen E. Corey, Naga Chalasani  Clinical.
Nat. Rev. Nephrol. doi: /nrneph
Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients 
Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity  Samyah Shadid, Michael D Jensen  Clinical Gastroenterology.
Volume 69, Issue 2, Pages (August 2018)
Stephen A. Harrison, MD, FACP  Clinical Gastroenterology and Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Diagnostic Value of Quantitative Hepatic Copper Determination in Patients With Wilson’s Disease  Peter Ferenci, Petra Steindl-Munda, Wolfgang Vogel, Wolfgang.
Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis  Zobair M. Younossi  Clinical.
Abstracts from Around the World
Impact of metabolic risk factors on HCC
Familial Aggregation of Insulin Resistance in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease  Manal F. Abdelmalek, Chen Liu,
Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients  Sven M.A. Francque, An Verrijken, Ilse Mertens, Guy Hubens,
Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients  Dima L. Diab, Lisa Yerian, Philip.
Michael Charlton  Clinical Gastroenterology and Hepatology 
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseasePowell EE, Cooksley WGE, Hanson R, Searle J,
Sensivity Sensivity Sensivity 100-specify 100-specify 100-specify
Elizabeth Mileti, Philip Rosenthal, Marion G. Peters 
Volume 140, Issue 1, Pages (January 2011)
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba  Gastroenterology 
The metabolomic window into hepatobiliary disease
Volume 41, Issue 3, Pages (September 2004)
Decision-Making Analysis for Surveillance
Volume 135, Issue 6, Pages (December 2008)
Presentation transcript:

STEATO-HEPATITIS IN OBESE PATIENTS SUBMITTED TO BARIATRIC SURGERY (BS): UTILITY OF CONTRAST-ENHANCED US WITH TIME- INTENSITY CURVES (CEUS-TIS) FOR DIAGNOSIS: INITIAL EXPERIENCE Francesco Giangregorio*, Edoardo Baldini &, Adriano Zangrandi £, Carlo Paties £, Fabio Fornari*, Patrizio Capelli &, *Gastroenterology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy & Surgery Department, Guglielmo da Saliceto Hospital, Piacenza, Italy £ Pathology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy Francesco Giangregorio*, Edoardo Baldini &, Adriano Zangrandi £, Carlo Paties £, Fabio Fornari*, Patrizio Capelli &, *Gastroenterology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy & Surgery Department, Guglielmo da Saliceto Hospital, Piacenza, Italy £ Pathology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy

INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathologic spectrum that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH)[1].1 It ’ s important establishing the diagnosis of NASH, both for prognosis and for indentifying potential candidates for future treatment protocols[2].2 Surgeons ’ evaluation could not identify NASH individuals. Routine liver biopsy during bariatric operations is mandatory to differentiate NASH and nonalcoholic fatty liver disease[3, 4].34 1.Miele L, Forgione A, Hernandez AP, Gabrieli ML, Vero V, Di RP, Greco AV, Gasbarrini G, Gasbarrini A, Grieco A: The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. EurRevMedPharmacolSci 2005, 9(5): Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009, 49(1): Charlton MR: Fibrosing NASH: On Being a Blind Man in a Dark Room Looking for a Black Cat (That Isn’t There). Gastroenterology 2011, 140(1): Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP: Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102(2): Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathologic spectrum that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH)[1].1 It ’ s important establishing the diagnosis of NASH, both for prognosis and for indentifying potential candidates for future treatment protocols[2].2 Surgeons ’ evaluation could not identify NASH individuals. Routine liver biopsy during bariatric operations is mandatory to differentiate NASH and nonalcoholic fatty liver disease[3, 4].34 1.Miele L, Forgione A, Hernandez AP, Gabrieli ML, Vero V, Di RP, Greco AV, Gasbarrini G, Gasbarrini A, Grieco A: The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. EurRevMedPharmacolSci 2005, 9(5): Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009, 49(1): Charlton MR: Fibrosing NASH: On Being a Blind Man in a Dark Room Looking for a Black Cat (That Isn’t There). Gastroenterology 2011, 140(1): Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP: Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102(2):

AIM Aim of the study was to understand if clinical data, blood examination, conventional US, colordoppler examination of splanchnic vasa or contrast-enhanced US with time-intensity curves studies were able to detect differences between simple steatosis from NASH.

MATERIALS from September 2010 to April 2012 we studied 75 morbidly obese patients (MOP), submitted to laparoscopic bariatric surgery (66 females; 9 males; mean age: 43,6 Y, range: 21-61; mean BMI 45,4 kg/m 2 ; all HBV and HCV negative patients). We collected clinical data, blood examinations, and the day before surgery patients were submitted to: – conventional US – colordoppler evaluation of Portal System – contrast-enhanced US with time intensity curves off-line elaborated with QONTRAST software (Bracco, Italy) from September 2010 to April 2012 we studied 75 morbidly obese patients (MOP), submitted to laparoscopic bariatric surgery (66 females; 9 males; mean age: 43,6 Y, range: 21-61; mean BMI 45,4 kg/m 2 ; all HBV and HCV negative patients). We collected clinical data, blood examinations, and the day before surgery patients were submitted to: – conventional US – colordoppler evaluation of Portal System – contrast-enhanced US with time intensity curves off-line elaborated with QONTRAST software (Bracco, Italy)

MATERIALS Clinical data: hepatomegaly Biochemical data: SGOT, SGPT, cholesterol, triglycerides, TSH Clinical data: hepatomegaly Biochemical data: SGOT, SGPT, cholesterol, triglycerides, TSH

MATERIALS conventional US (hepatomegaly, irregular margins, steatosis, splenomegaly) colordoppler evaluation of Portal System (Portal vein diameter, mean blood flow velocity, hepatic and splenic artery resistence index) contrast-enhanced US with time intensity curves off-line elaborated with QONTRAST software (Bracco, Italy) ) (CEUS-TIS); time to peak (TTP); peak% (P%); red blood volume (RBV) and flow (RBF); mean time to transit (MTT)). conventional US (hepatomegaly, irregular margins, steatosis, splenomegaly) colordoppler evaluation of Portal System (Portal vein diameter, mean blood flow velocity, hepatic and splenic artery resistence index) contrast-enhanced US with time intensity curves off-line elaborated with QONTRAST software (Bracco, Italy) ) (CEUS-TIS); time to peak (TTP); peak% (P%); red blood volume (RBV) and flow (RBF); mean time to transit (MTT)).

77

88 Portal Vein Hepatic Vein Hepatic arterySplenic artery

9 arterial phaseportal phase late phase

10

METHODS Liver biopsy was performed during bariatric surgery. Clinical, ultrasonographic, colordoppler and CEUS-TIS data were compared to hystology; sensitivity (sens), specificity(spec), diagnostic accuracy(DA), positive predictive (PPV) and negative predictive value (NPV) were calculated; comparison among data were performed with receiver operating curves (ROC) (spss version 18); Z test was calculated to evaluate statistical significance among AUC-ROC (p 1.96) Liver biopsy was performed during bariatric surgery. Clinical, ultrasonographic, colordoppler and CEUS-TIS data were compared to hystology; sensitivity (sens), specificity(spec), diagnostic accuracy(DA), positive predictive (PPV) and negative predictive value (NPV) were calculated; comparison among data were performed with receiver operating curves (ROC) (spss version 18); Z test was calculated to evaluate statistical significance among AUC-ROC (p 1.96)

12 RESULTS: data Hystologic diagnosis: ① 57 non pathological normal:12 steatosis: 45 (30 initial, 15 overt steatosis) ② 18 pathological 12 initial steatohepatitis 6 overt hepatitis

13 RESULTS: data

RESULTS: statistical analysis

15 RESULTS: auc ROC

SUMMARY Clinical and ultrasonographic criteria are not useful for discriminating simple steatosis from steato-hepatitis in obese patients. Only CEUS –TIS may help to establishing the diagnosis of NASH in a non-invasive way Clinical and ultrasonographic criteria are not useful for discriminating simple steatosis from steato-hepatitis in obese patients. Only CEUS –TIS may help to establishing the diagnosis of NASH in a non-invasive way

17 Grazie dell ’ attenzione!!!